Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 16/20 | 1.00 |
| ▸ | ATM | Q13315 | 3/20 | 0.49 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19259991 | 0.82 | PIK3C3 (0.69) | PIK3C3ATM | |
| SCHEMBL19259552 | 0.81 | PIK3C3 (1.00) | PIK3C3 | |
| SCHEMBL19259436 | 0.81 | PIK3C3 (1.00) | PIK3C3 | |
| SCHEMBL824821 | 0.78 | PIK3C3 (0.64) | PIK3C3CNR2ZAP70 | |
| SCHEMBL17819728 | 0.78 | PIK3C3 (0.64) | PIK3C3ATMPIK3CAPIK3CB | |
| SCHEMBL17921651 | 0.76 | PIK3C3 (0.60) | PIK3C3ATM | |
| SCHEMBL23477915 | 0.75 | PIK3C3 (0.59) | PIK3C3ATMPIK3CB | |
| SCHEMBL17819933 | 0.75 | PIK3C3 (0.59) | PIK3C3ATMPIK3CAPIK3CB | |
| SCHEMBL17921644 | 0.75 | PIK3C3 (0.59) | PIK3C3ATMPIK3CAPIK3CB | |
| SCHEMBL19259409 | 0.73 | PIK3C3 (0.56) | PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2025-04-24 | — | — | US | claimed |
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | claimed |
| CN-118201619-A | Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-06-14 | — | — | CN | claimed |
| US-20240050439-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | Spring Bioscience AB (SE) | 2024-02-15 | — | — | US | claimed |
| CN-117136062-A | Antiviral activity of VPS34 inhibitors | 德西费拉制药有限责任公司 | 2023-11-28 | — | — | CN | claimed |
| US-11633403-B2 | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes | SPRINT BIOSCIENCE AB (SE) | 2023-04-25 | — | — | US | claimed |
| WO-2023019259-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-02-16 | — | — | WO | claimed |
| US-20220184092-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2022-06-16 | — | — | US | claimed |
| US-20220117974-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2022-04-21 | — | — | US | claimed |
| CN-108698996-B | 6-aryl-4-morpholin-1-ylpyridinone compounds useful for the treatment of cancer and diabetes | 思普瑞特生物科学公司 | 2021-10-01 | — | — | CN | claimed |
| US-11077113-B2 | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes | SPRINT BIOSCIENCE AB (SE) | 2021-08-03 | — | — | US | claimed |
| US-20210128571-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2021-05-06 | — | — | US | claimed |
| EP-3416945-B1 | 6-ARYL-4-(MORPHOLIN-4-YL)-1H-PYRIDIN-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2020-07-01 | — | — | EP | claimed |
| EP-3416945-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | Sprint Bioscience AB (SE) | 2018-12-26 | — | — | EP | claimed |
| WO-2017140841-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2017-08-24 | — | — | WO | claimed |
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2025-04-24 | — | — | US | disclosed |
| EP-4384180-A1 | COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-3416945-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | Sprint Bioscience AB (SE) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017140841-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017140841-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127790-A1 | COMBINATION THERAPY USING VPS34 INHIBITORS | STING1, TBK1, VPS4B | PIK3C3 1649/4885ATM 384/4885CNR2 3953/4885 |
| US-20220117974-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | PYCR1, GPR119, IL6 | PIK3C3 4453/4885ATM 3094/4885CNR2 1602/4885 |
| US-20220184092-A1 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | SARS1, VPS26B, VPS4B | PIK3C3 1967/4885ATM 3286/4885CNR2 4793/4885 |
| US-11077113-B2 | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes | PYCR1, GPR119, IL6 | PIK3C3 4453/4885ATM 3094/4885CNR2 1602/4885 |
| US-11633403-B2 | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes | PYCR1, GPR119, IL6 | PIK3C3 4453/4885ATM 3094/4885CNR2 1602/4885 |
| US-20210128571-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | GPR119, PYCR1, CDK6 | PIK3C3 4690/4885ATM 2752/4885CNR2 1155/4885 |
| US-20240050439-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | PYCR1, GPR119, CDK6 | PIK3C3 4489/4885ATM 3112/4885CNR2 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.